In previous studies we found a significant elevation of proteolytic fragments of complement C4 in biological fluids from lung cancer patients using a commercial ELISA based on the detection of C4d-containing fragments (C4b, iC4b and C4d) [15–16]. This evidence concerns the gene C4A and lung carcinoma.